JUPITER NEUROSCIENCES, INC.
JUNSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $21,796 | $0 | — |
| Operating income | −$8.9M | −$3.1M | −$3.9M |
| Net income | −$8.6M | −$2.4M | −$4.8M |
| Total assets | $5.6M | $6.2M | $148,592 |
| Total liabilities | $7.4M | $2.0M | $5.9M |
| Equity | −$1.8M | $4.2M | −$5.8M |
| EPS (diluted) | $-0.25 | $-0.08 | $-0.18 |
| Shares out. | 33.1M | 33.1M | 26.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −40873.2%
- Net margin
- −39662.8%
- Return on equity
- 471.9%
- Return on assets
- −155.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 132.9%
- Debt / equity
- —
- Book value / share
- $-0.06
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -34.36distress
- Accruals / assets
- −58.1%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Elmasri SaleemOfficer — CFO and Secretary | Jun 2, 2025 | Option exercise | 66,293 | $0.00 |
| Silva Alison D.Officer — Pres + Chief Business Officer | Jul 1, 2025 | Buy | 250 | $1.03 |
| Rosen ChristerOfficer — CEO and Chairman | Jul 1, 2025 | Buy | 500 | $1.01 |
| Silva Alison D.Officer — Pres + Chief Business Officer | Jun 2, 2025 | Option exercise | 110,227 | $0.00 |
| Rosen ChristerOfficer — CEO and Chairman | Jun 2, 2025 | Option exercise | 497,396 | $0.00 |
| Weis HolgerDirector | Jan 22, 2025 | Option exercise | 10,781 | — |
| Brady Allison WDirector | Jan 22, 2025 | Option exercise | 21,750 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 87,758 | 1.2 | +28.8% |
| Apr 30, 2026 | 68,135 | 1.0 | -9.8% |
| Apr 15, 2026 | 75,528 | 1.0 | -40.5% |
| Mar 31, 2026 | 126,917 | 1.0 | +59.6% |
| Mar 13, 2026 | 79,512 | 1.0 | -63.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Other material eventMay 21, 2026
- Regulation FD disclosure · Other material eventMay 20, 2026
- Delisting / listing-standard notice · Regulation FD disclosureFeb 27, 2026
- Entered a material agreement · New financial obligationFeb 20, 2026
- Entered a material agreement · New financial obligation · Unregistered equity saleDec 23, 2025
- Director / officer change · Amended charter or bylaws · Shareholder voteDec 22, 2025
- Entered a material agreement · New financial obligation · Unregistered equity sale · Regulation FD disclosureOct 27, 2025
- Other material eventJul 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.